Secondary resistance to immunotherapy associated with ?-catenin pathway activation or PTEN loss in metastatic melanoma.
Secondary resistance to immunotherapy associated with ?-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.